Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Edward A. Faber Jr. is a medical oncologist, hematologist and blood and marrow transplant specialist at OHC. He has a special interest in malignant hematology, benign hematology, and autologous and allogeneic bone marrow transplantation. Dr. Faber is a principal investigator for multiple myeloma clinical trials at OHC and a member of OHC’s CAR T-cell therapy team, the only cancer experts in the region certified to offer this revolutionary treatment to adults with blood cancers.
After completing his undergraduate degree, Dr. Faber received a Master of Science degree in Genetics and Molecular Biology from Duquesne University while supervising the Molecular Diagnostics Lab at the Western Pennsylvania Cancer Institute.
He received his medical degree Lake Erie College of Osteopathic Medicine, and competed a dual residency in osteopathic and allopathic medicine at the University of Pittsburgh Medical Center (UPMC) – Mercy Hospital. He completed his residency in internal medicine at UPMC and a fellowship in hematology and oncology at Michigan State University. Dr. Faber is board-certified in internal medicine, and medical oncology and hematology by the American Board of Internal Medicine.
Dr. Faber served as an assistant professor of medicine at the University of Nebraska Medical Center and served as a multiple myeloma and Waldenstrom’s macroglobulinemia panel member for the National Comprehensive Cancer Network. Dr. Faber is a national physician advisor for the education project of the Association of Community Cancer Centers: Improving Quality Care for Multiple Myeloma, and has been appointed as an advisory panelist for amyloidosis for the American Society for Clinical Oncology’s cancer.net editorial board.
Among his many awards, he was nominated as the “Man of the Year” by The Leukemia & Lymphoma Society (LLS) in 2013.